OXFORD, England--(BUSINESS WIRE)--Immunocore Limited, a world-leading biotechnology company with a highly innovative immune-oncology T cell receptor platform technology, today announces that Eliot Forster, Chief Executive Officer, will present a corporate overview at the Cowen and Company 35th Annual Health Care Conference in Boston today. The CEO’s presentation will take place at 8 am EST at The Boston Marriott Copley Place, Boston, Massachusetts (MIT Room, 3rd Floor).
Additionally, Eva-Lotta Allan, Chief Business Officer, will host investor meetings and provide a corporate overview at the Credit Suisse One-on-One Healthcare Conference in London on Tuesday 3 March 2015.
Notes for editors
Immunocore is one of the world’s leading biotechnology companies, with a highly innovative immune-oncology platform technology called ImmTACs. ImmTACs are a novel class of biologic drugs based on the Company’s proprietary T cell receptor (TCR) technology which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases. Immunocore, based on decades of world-leading scientific innovation in the discovery of HLA targets and T cell receptor technology, has a pipeline of wholly-owned and partnered ImmTAC programmes with robust clinical data, validated by industry partnerships with world-leading pharmaceutical companies. Immunocore aims to leverage the utility of its platform across a wide range of indications to become a Premier Biotech company and world-leader in its field.
Immunocore’s world-leading science and strong IP position has attracted major pharmaceutical companies including Genentech, GlaxoSmithKline, MedImmune, the biologics division of AstraZeneca, via discovery collaborations, as well as a co-discovery and co-development partnership with Lilly. Founded in 2008 originally out of Oxford University and headquartered outside Oxford, Immunocore now has more than 140 staff. Immunocore is well funded and owned by a group of long-term private investors. For more information, please visit www.immunocore.com
Immunocore’s proprietary technology is focused on small (peptide) molecules called ImmTACs (Immune mobilising mTCR Against Cancer) that enable the immune system to recognise and kill cancerous or bacterially/virally infected cells.
Immunocore's ImmTACs, a new class of drug with ultra-high affinity for intracellular cancer targets, are synthetic, soluble T cell receptors (TCRs) that recognise diseased cells containing cancer/viral specific targets. The ImmTACs enable circulating T-cells to selectively identify and kill diseased cells. The ImmTAC platform is unique and has broad applicability to a wide range of intracellular targets and disease indications. ImmTACs can access up to nine-fold more targets than typical antibody-based therapies, including monoclonal antibodies.
TCRs naturally recognise diseased cells and Immunocore’s world-leading competitive advantage is its ability to engineer high affinity TCRs and link them to an antibody fragment that activates the immune system to kill the targeted diseased cells. The most advanced ImmTAC, IMCgp100, is currently in Phase IIa clinical trials for the treatment of late stage melanoma. Immunocore has a growing internal pipeline of ImmTACs addressing many different cancer types and has developed a broad database of intracellular cancer targets.
ImmTACs can address a significantly larger range of disease indications than currently respond to existing immune oncology agents and combine the characteristics of very high potency, encouraging safety and low cost of goods.